Inventiva S.A. American Depository Shares

Claret Capital Partners has invested €43m in clinical-stage biopharmaceutical company Inventiva as part of a €130m debt financing round. Inventiva is developing lanifibranor, an oral therapy for MASH (metabolic dysfunction-associated steatohepatitis), with Phase 3 trial results expected in Q4 2026. The financing, alongside BlackRock-managed f...

Inventiva completed repayment of €62 million in EIB loans and repurchased EIB warrants for €50 million. The company simultaneously issued €75 million in new debt financing (€35 million convertible bonds and €40 million amortized bonds) from BlackRock and Claret Capital Partners, following a successful €120 million equity offering of A...

Inventiva, a clinical-stage biopharmaceutical company developing oral therapies for MASH, announced the availability of preparatory documents for its Combined General Meeting scheduled for June 30, 2026. The meeting agenda includes a 39th resolution related to a master agreement with the European Investment Bank (EIB) for full repayment of existi...

Inventiva, a clinical-stage biopharmaceutical company, announced the resumption of trading for its ordinary shares on Euronext Paris and provided information on its Combined General Meeting scheduled for June 30, 2026. As of May 22, 2026, the company had 209,007,475 shares in circulation with 218,082,368 total voting rights.

Inventiva announced the arrangements for its Mixed General Assembly scheduled for June 30, 2026 in Paris. The agenda includes a 39th resolution regarding a master agreement with the European Investment Bank (EIB) signed on June 1, 2026, which involves full repayment of existing EIB loans and repurchase of warrant subscription rights (BSA) for €...